Guidant
-
Devices & Diagnostics, Hospitals, Policy
BSX to pay $30M to end allegations Guidant sold defective defibrillators to Medicare
Guidant continues to prove itself as Boston Scientific’s biggest legal headache. Reuters reports Boston Scientific (BSX) […]
-
Devices & Diagnostics, Hospitals, Startups
Could this device lead to shorter labor and delivery + become childbirth standard of care?
Materna Medical is at work on a device to help protect the more than 80 […]
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
Using Red Wine to Coat Stents and Balloons | Interview with John Foley of Requisite Biomedical
Is red wine the next breakthrough therapy in the world of drug-eluting stents and balloons? […]
-
Devices & Diagnostics, MedCity Influencers
Boston Scientific pacemaker subsidiary dodges class-action suit again
A federal judge in California dismissed for the second time a purported class-action lawsuit against Boston Scientific’s star-crossed Guidant Corp. pacemaker subsidiary.
-
Devices & Diagnostics, MedCity Influencers
BSX: Federal Guidant lawsuit ‘should not have a significant financial impact’
The Massachusetts-based maker of new innovative medical devices says the federal government’s lawsuit over Guidant defibrillators “should not have a significant financial impact.” The Justice Department filed a civil lawsuit on Thursday accusing Guidant, which Boston Scientific acquired in 2006 for $27 billion, of causing healthcare providers to file fraudulent Medicare claims.
-
Federal suit targets Boston Scientific, Guidant (Morning Read)
Among today’s current medical news: Guidant a lawsuit target (again); Merck beefs up its biotech; hospitals and docs upped their lobbying efforts; Baby Boomers’ Alzheimer’s problems; and just who has an MD?
-
Devices & Diagnostics, MedCity Influencers
Boston Scientific inherits Guidant’s $525 million tax bill
The Internal Revenue Service wants Boston Scientific to pony up $525.1 million plus interest on back taxes owed by BSX subsidiary Guidant Corp.
-
Justice Department joins defibrillator suit against Guidant
The federal government reversed course and decided to intervene in a false claims lawsuit filed […]
-
Trayt Health Seeks to Increase Access to Diagnoses and Treatments
CEO Malekeh Amini explains how Trayt Health can bridge the gap for patients seeking neurological care.
-
Devices & Diagnostics, MedCity Influencers
Boston Scientific, Guidant suit won’t go to High Court
Boston Scientific’s subsidiary Guidant was involved in a six-year dispute over the Ancure device. The plaintiffs claimed the medical device, which was used to treat abdominal aortic aneurysm treatment, caused them severe damage. The Supreme Court declined to hear the appeal.
-
Is Boston Scientific selling the wrong business to Stryker?
Boston Scientific Corp. (NYSE:BSX) finally pulled the trigger Thursday, saying it would sell a major business to Stryker Corp. It just wasn’t the business Wall Street was expecting it to sell.
-
Former Guidant president walks from Abiomed board
Ronald Dollens, the former president and CEO of Guidant Corp., is walking away from his board seat at Abiomed Inc. with one year left on his term. Dollens, who joined the board of the Danvers, Massachusetts-based heart pump maker in 2006, was set to have his board term expire in 2011.
-
Tale of two Boston Scientifics
Earlier this week, I e-mailed the head of media relations at Boston Scientific Corp. (NYSE: BSX) on a story about a lawsuit. Not really expecting him to return my message (he didn’t and never does), I cced Steve Goodyear, an all round good guy who handles media calls for the company’s cardiovascular division in Maple Grove.
-
Devices & Diagnostics, MedCity Influencers
Boston Scientific’s Guidant settlement rejected by judge
A federal judge today rejected a $296 million plea agreement between the U.S. Justice Dept. […]
-
Minnesota docs: Prosecute, don’t settle, over Guidant
Two Minneapolis Heart Institute doctors are opposing a $296 million plea agreement involving Boston Scientific […]